Journal of Shandong University (Health Sciences) ›› 2020, Vol. 58 ›› Issue (4): 100-104.doi: 10.6040/j.issn.1671-7554.0.2019.1418

Previous Articles    

Correlation between anti-müllerian hormone and natural reproductive potential in women

GAO Renyuan1, ZHANG Jing2, LIU Fangfang2, LI Ruijing2, ZHANG Xiuqing3, QIN Yingying1   

  1. 1. Department of Reproductive Endocrinology, Center for Reproductive Medicine, Shandong University, Jinan 250021, Shandong, China;
    2. Department of Health Management, Center for Reproductive Medicine, Shandong University, Jinan 250021, Shandong, China;
    3. Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Published:2022-09-27

Abstract: Objective To evaluate the relationship between serum level of anti-müllerian hormone(AMH)and natural reproductive potential in women of childbearing age. Methods Clinical data of 601 women who underwent physical examination during Jan. 2016 and May 2018 were collected. The patients were divided into two groups: young age group(≤35 years old, n=292)and advanced age group(>35 years old, n=309). According to the level of AMH, the two group were further divided into three subgroups: low AMH(<1.0 ng/mL), normal AMH(1.0~3.5 ng/mL)and high AMH(>3.5 ng/mL)groups. All women were followed up for 12 months to observe the natural conception 山 东 大 学 学 报 (医 学 版)58卷4期 -高任远,等.抗苗勒管激素与女性自然妊娠能力的关联分析 \=-rate. Results During the follow-up of 12 months, 202(33.61%)participants were pregnant. The clinical pregnancy rate was 53.42%(156/292)in the young age group and 14.89%(46/309)in the advanced age group. In the young age group, the clinical pregnancy rate in high, normal and low AMH subgroups was 54.97%(94/171), 56.38%(53/94)and 33.33%(9/27), respectively, with no significant difference(P=0.09). In the advanced age group, the clinical pregnancy rate in high, normal and low AMH subgroups was 35.71%(15/42), 21.10%(23/109)and 5.06%(8/158), respectively. A strong correlation was observed between AMH and natural conception rate(P<0.05). The ROC curve showed that AMH had certain predictive value for natural reproductive potential in the advanced age group(AUCAMH=0.74). Conclusion Serum level of AMH is a promising predictor for fertility in advanced age women, but not in young women.

Key words: Anti-müllerian hormone, Age, Natural conception, Fertility

CLC Number: 

  • R711.75
[1] 秦莹莹, 张茜蒻. 卵巢早衰的免疫学病因及免疫干预研究进展[J]. 山东大学学报(医学版), 2018, 56(4): 33-37. QIN Yingying, ZHANG Xiruo. Research advances on the immunological pathogenesis and immunotherapy of premature ovarian failure[J]. Journal of Shandong University(Health Science), 2018, 56(4): 33-37.
[2] Broer SL, Broekmans FJ, Laven JS, et al. Anti-müllerian hormone: ovarian reserve testing and its potential clinical implications[J]. Hum Reprod Update, 2014, 20(5): 688-701.
[3] Bertone-Johnson ER, Manson JE, Purdue-Smithe AC, et al. Anti-müllerian hormone levels and incidence of early natural menopause in a prospective study[J]. Hum Reprod, 2018, 33(6): 1175-1182.
[4] Tal R, Seifer DB. Ovarian reserve testing: a users guide[J]. Am J Obstet Gynecol, 2017, 217(2): 129-140.
[5] Dewailly D, Laven J. AMH as the primary marker for fertility[J]. Eur J Endocrinol, 2019, 181(6): D45-D51.
[6] Zarek SM, Mitchell EM, Sjaarda LA, et al. Is anti-müllerian hormone associated with fecundability? Findings from the EAGeR trial[J]. J Clin Endocrinol Metab, 2015, 100(11): 4215-4221.
[7] Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age[J]. JAMA, 2017, 318(14): 1367-1376.
[8] Hagen CP, Vestergaard S, Juul A, et al. Low concentration of circulating anti-müllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study[J]. Fertil Steril, 2012, 98(6): 1602-1608.
[9] Hawkins Bressler L, Steiner A. Anti-müllerian hormone as a predictor of reproductive potential[J]. Curr Opin Endocrinol Diabetes Obes, 2018, 25(6): 385-390.
[10] Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone[J]. Fertil Steril, 2013, 99(7): 1825-1830.
[11] Cui L, Qin Y, Gao X, et al. Anti-müllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause[J]. Fertil Steril, 2015, 105(2): 481-485.
[12] Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology[J]. Hum Reprod, 2006, 21(1): 159-163.
[13] Fanchin R, Mendez Lozano DH, Frydman N, et al. Anti-müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization[J]. J Clin Endocrinol Metab, 2007, 92(5): 1796-1802.
[14] Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number[J]. Fertil Steril, 2011, 95(1): 170-175.
[15] Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3):370-385.
[16] Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-müllerian hormone is associated with oocyte quality in stimulated cycles[J]. Hum Reprod, 2006, 21(8): 2022-2026.
[17] 李蓉, 杨蕊, 刘嘉茵. 卵巢低反应诊疗的再思考[J]. 中华生殖与避孕杂志, 2019, 39(9): 695-698. LI Rong, YANG Rui, LIU Jiayin, et al. A reconsideration of diagnosis and treatment of poor ovarian response[J]. Chinese Journal Reprod Uction Contracep tion, 2019, 39(9): 695-698.
[18] Zhang B, Meng Y, Jiang X, et al. IVF outcomes of women with discrepancies between age and serum anti-Müllerian hormone levels[J]. Reprod Biol Endocrinol, 2019, 17(1): 58. doi: 10.1186/s12958-019-0498-3.
[19] 李梅. 高龄女性的卵子和胚胎质量[J]. 山东大学学报(医学版), 2017, 55(1): 16-21. LI Mei. Quality of oocytes and embryos of elder women[J]. Journal of Shandong University(Health Science), 2017, 55(1): 16-21.
[20] Qiao J, Wang ZB, Feng HL, et al. The root of reduced fertility in aged women and possible therapentic options: current status and future perspects[J]. Mol Aspects Med, 2014, 38: 54-85. doi:10.1016/j.mam.2013.06.001.
[21] May-Panloup P, Boucret L, Chao de la Barca JM, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles[J]. Hum Reprod Update, 2016,22(6): 725-743.
[22] Ben-Meir A, Burstein E, Borrego-Alvarez A, et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging[J]. Aging Cell, 2015, 14(5): 887-895.
[23] Al-Edani T, Assou S, Ferrières A, et al. Female aging alters expression of human cumulus cells genes that are essential for oocyte quality[J]. Biomed Res Int, 2014, 2014: 964614. doi: 10.1155/2014/964614.
[24] Grøndahl ML, Yding Andersen C, Bogstad J, et al. Gene expression profiles of single human mature oocytes in relation to age[J]. Hum Reprod, 2010, 25(4): 957-968.
[25] Tatsumi T, Ishida E, Tatsumi K, et al. Advanced paternal age alone does not adversely affect pregnancy or live-birth rates or sperm parameters following intrauterine insemination[J]. Reprod Med Biol, 2018, 17(4): 459-465.
[26] Simon L, Murphy K, Shamsi MB, et al. Paternal influence of sperm DNA integrity on early embryonic development[J]. Hum Reprod, 2014, 29(11): 2402-2412.
[1] LI Bo-Bo, LI Dao-Tang, LIU Shu-Guang, WANG Xing-Wu. Expression of serum DKK-1 in esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 58-61.
[2] LI Ping, HE Xuemei. Fertility assessment of women [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 8-11.
[3] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[4] WU Ruifang, LI Changzhong. Status and progress of female fertility protection [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 1-7.
[5] SHI Yuhua, PAN Ye, XIE Yanqiu. Latest advances of embryo cryopreservation technology [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 12-18.
[6] YAN Lei, YUE Caixin, LIU Yichun. Fertility preservation in patients with endometriosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 31-34.
[7] LU Qun, ZHAO Lulu. Progress on assisted reproductive technology for women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertilitysparing treatment [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 35-41.
[8] LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[9] HAO Guimin, LUO Zhuoye, WANG Yizhuo. Ethical issues and considerations in fertility preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 47-52.
[10] XU Kai, HAN Chao, DING Shouluan, DING Xuan, XING Deguang, WANG Chengwei. Factors of preoperative rebleeding in 181 patients with poor-grade aneurysmal subarachnoid hemorrhage [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 97-101.
[11] XU Xiaofen, ZHU Xiao, MA Wei, LI Na. Influencing factors of cancer pain management disorder in 123 cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 119-124.
[12] Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[13] Xiaofang YI,Jihua HUANG. Patient education and proper management of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 32-35.
[14] Chao PENG,Yingfang ZHOU. Progress on the medical treatment of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 20-25.
[15] Jinhua LENG,Jinghua SHI. Clinical manifestations of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 1-5.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!